ABBVIE
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 352
- Registration Number
- NCT04908475
- Locations
- 🇺🇸
Epiphany Dermatology of Kansas LLC /ID# 229221, Overland Park, Kansas, United States
🇺🇸Center for Clinical Studies - Houston (Binz) /ID# 229272, Houston, Texas, United States
🇺🇸UC Davis Health /ID# 229133, Sacramento, California, United States
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
- Conditions
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 286
- Registration Number
- NCT04903626
- Locations
- 🇺🇸
Duplicate_University Of Cincinnati Medical Center /ID# 226922, Cincinnati, Ohio, United States
🇮🇹IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 227080, Bologna, Emilia-Romagna, Italy
🇺🇸Arizona Health Research /ID# 233558, Chandler, Arizona, United States
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT04895410
- Locations
- 🇺🇸
Moffitt Cancer Center /ID# 229939, Tampa, Florida, United States
🇺🇸Norton Cancer Institute - St Matthews /ID# 229319, Louisville, Kentucky, United States
🇺🇸University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309, Ann Arbor, Michigan, United States
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 75
- Registration Number
- NCT04895436
- Locations
- 🇮🇹
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 229504, Torino, Piemonte, Italy
🇬🇧Blackpool Victoria Hospital /ID# 267280, Blackpool, Lancashire, United Kingdom
🇺🇸Des Moines Oncology Research Association /ID# 232606, Des Moines, Iowa, United States
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 473
- Registration Number
- NCT04888585
- Locations
- 🇺🇸
Purushotham & Akther Kotha MD, Inc /ID# 228120, La Mesa, California, United States
🇺🇸International Medical Research /ID# 228069, Daytona Beach, Florida, United States
🇺🇸Neoclinical Research /ID# 228753, Hialeah, Florida, United States
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 124
- Registration Number
- NCT04880876
- Locations
- 🇺🇸
Florida Research Center, Inc. /ID# 227597, Miami, Florida, United States
🇺🇸Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 227600, Stockbridge, Georgia, United States
🇺🇸Preferred Primary Care Physicians, Inc. /ID# 227596, Pittsburgh, Pennsylvania, United States
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 132
- Registration Number
- NCT04862286
- Locations
- 🇩🇪
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 243883, Kiel, Schleswig-Holstein, Germany
🇺🇸First OC Dermatology /ID# 226942, Fountain Valley, California, United States
🇺🇸Solutions Through Adv Rch /ID# 226104, Jacksonville, Florida, United States
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT04853368
- Locations
- 🇺🇸
University of Southern California /ID# 249147, Los Angeles, California, United States
🇺🇸UH Cleveland Medical Center /ID# 245433, Cleveland, Ohio, United States
🇺🇸Boston Children's Hospital /ID# 248646, Boston, Massachusetts, United States
A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib
- Conditions
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 650
- Registration Number
- NCT04846244
- Locations
- 🇬🇷
University General Hospital of Patras /ID# 243795, RION Patras Achaia, Greece
🇧🇪ReumaClinic /ID# 231438, Genk, Belgium
🇦🇷Hospital Italiano La Plata /ID# 230779, La Plata, Buenos Aires, Argentina
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 818
- Registration Number
- NCT04846959
- Locations
- 🇺🇸
Evidera, a PPD Business Unit /ID# 238688, Morrisville, North Carolina, United States
🇺🇸PPD Development, LP /ID# 232134, Wilmington, North Carolina, United States